Side-by-side comparison of AI visibility scores, market position, and capabilities
Major ambulatory EHR serving 150K providers bootstrapped to scale; Sunoh.ai ambient clinical documentation and revenue cycle management competing with Epic and athenahealth for practices.
eClinicalWorks is one of the largest electronic health record (EHR) and practice management software providers in the United States, serving approximately 150,000 providers across 850,000 care sites with ambulatory EHR, revenue cycle management, patient engagement, and population health tools. Founded in 1999 by Girish Navani and headquartered in Westborough, Massachusetts, eClinicalWorks is privately held and is notable for being a bootstrapped company that has grown to significant scale without venture capital funding, generating substantial annual revenue from its large installed physician base.\n\neClinicalWorks' platform covers the ambulatory (outpatient) clinical workflow: clinical documentation with specialty-specific templates, order entry for labs and imaging, e-prescribing, chronic disease management registries, telehealth (healow TeleVisits), and patient portal. The revenue cycle management capabilities handle insurance claims submission, denial management, and patient billing. Population health tools enable practices and health systems to identify at-risk patient populations and coordinate care across attributed patients.\n\nIn 2025, eClinicalWorks competes with Epic (the dominant health system EHR), athenahealth (cloud-native ambulatory EHR), Oracle Health (Cerner), and Modernizing Medicine for physician practice EHR market share. The company has faced regulatory challenges — in 2017, eClinicalWorks paid $155 million to settle Department of Justice charges related to EHR certification fraud. Despite this, the company retained most of its customer base due to high switching costs inherent in EHR changes. The 2025 strategy focuses on its AI assistant Sunoh.ai (ambient clinical documentation that automatically generates SOAP notes from recorded patient visits), expanding telehealth capabilities, and growing the healow patient engagement platform.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.